No black box warning on record for Dihydroergotamine Mesylate

As of the latest FDA labeling reviewed, Dihydroergotamine Mesylate (DIHYDROERGOTAMINE MESYLATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Dihydroergotamine Mesylate medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Dihydroergotamine Mesylate Injection should only be used where a clear diagnosis of migraine headache has been established. CYP3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of dihydroergotamine and potent CYP3A4 inhibitors, such as protease inhibitors and macrolide antibiot

No black box warning on record for Dihydroergotamine Mesylate

Other warnings & precautions

WARNINGS Dihydroergotamine Mesylate Injection should only be used where a clear diagnosis of migraine headache has been established. CYP3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of dihydroergotamine and potent CYP3A4 inhibitors, such as protease inhibitors and macrolide antibiot

Dihydroergotamine Mesylate Black Box Warning

No black box warning on record for Dihydroergotamine Mesylate

Other warnings & precautions

Dihydroergotamine Mesylate Black Box Warning

No black box warning on record for Dihydroergotamine Mesylate

Other warnings & precautions